Pembrolizumab and sintilimab have shown more pronounced survival benefits in patients with high PD-L1 expression (CPS ≥ 10), with pembrolizumab also demonstrating efficacy in patients with oesophageal adenocarcinoma. Here, CD274 is linked to esophageal adenocarcinoma.